Bio tech company updates — 9/13/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Samsung Biologics has secured a major $262 million manufacturing contract extending to 2033, significantly boosting its lifetime contracted value. Meanwhile, SK Biopharmaceuticals shares dropped following an FDA partial clinical hold on its epilepsy drug candidate, and local governments in Yeoncheon and Chungbuk announced new strategic partnerships to expand the bio-industry footprint.
Key Findings
- Samsung Biologics Contract Expansion: The company signed a $262 million manufacturing agreement running through 2033, pushing its total lifetime contracted value past $21.9 billion.
- SK Biopharmaceuticals Clinical Setback: Shares fell 6.24% after the U.S. FDA placed a partial clinical hold on the epilepsy drug candidate opacalim, halting new patient enrollment.
- Regional Bio-Industry Growth: Yeoncheon County partnered with KOSME to develop the green bio industry in northern Gyeonggi, while North Chungcheong Province unveiled a 3.1 trillion won strategy targeting 30,000 jobs.
Details
Samsung Biologics Secures Long-Term CDMO Revenue
Samsung Biologics continues to solidify its position as a global Contract Development and Manufacturing Organization (CDMO) leader. A newly announced $262 million contract extends through 2033, a move that lifts the company's lifetime contracted value past $21.9 billion. This deal highlights the continued demand for large-scale biologics manufacturing capacity in South Korea.
SK Biopharmaceuticals Faces Regulatory Headwinds
In contrast to Samsung's expansion, SK Biopharmaceuticals experienced a sharp stock decline of 6.24% on September 11, 2026. The drop followed the FDA's decision to place a partial clinical hold on "opacalim," an epilepsy drug candidate. The hold specifically halts new patient enrollment, marking a significant regulatory hurdle for the company's pipeline.
Regional Governments Push Bio-Industry Clusters
Local authorities are actively seeking to decentralize and expand the bio-sector beyond traditional hubs like Incheon and Seoul. On September 11, Yeoncheon County signed an agreement with the Ministry of SMEs and Startups (via KOSME) to foster the green bio industry in northern Gyeonggi, focusing on policy funds and export support. Additionally, North Chungcheong Province (Chungbuk) recently detailed a 3.1 trillion won bio-industry strategy aimed at creating 30,000 jobs and inducing 4.4 trillion won in production.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
